Argenx
ARGX
#476
Rank
C$71.42 B
Marketcap
C$1,143
Share price
-1.72%
Change (1 day)
38.68%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): C$12.46

According to Argenx 's latest financial reports the company's current EPS (TTM) is C$12.15. In 2024 the company made an earnings per share (EPS) of C$19.07 an increase over its 2023 EPS that were of C-$7.07.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$12.46-34.64%
2024C$19.07-369.77%
2023C-$7.07-60.46%
2022C-$17.8763.33%
2021C-$10.94-40.37%
2020C-$18.35183.47%
2019C-$6.47123.09%
2018C-$2.9054.93%
2017C-$1.8714.07%
2016C-$1.6413.05%
2015C-$1.45-36.34%
2014C-$2.28209.04%
2013C-$0.74-33.99%
2012C-$1.12185.59%
2011C-$0.39